Press Releases ALL > Press Release - 2026-05-13 Celea Therapeutics – Deupirfenidone (LYT-100) PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference Continue Press Release - 2026-05-01 Seaport PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering Continue Press Release - 2026-04-29 Other PureTech Announces Annual Results for Year Ended December 31, 2025 Continue Publications ALL > Publications 2026-04-02 Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial Full Article Publications 2026-03-25 An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans Full Article Publications 2025-05-08 Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study Full Article @PureTechH Tweets by PureTechH
Press Releases ALL > Press Release - 2026-05-13 Celea Therapeutics – Deupirfenidone (LYT-100) PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference Continue Press Release - 2026-05-01 Seaport PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering Continue Press Release - 2026-04-29 Other PureTech Announces Annual Results for Year Ended December 31, 2025 Continue Publications ALL > Publications 2026-04-02 Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial Full Article Publications 2026-03-25 An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans Full Article Publications 2025-05-08 Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study Full Article @PureTechH Tweets by PureTechH
